Emma Guttman
Icahn School of Medicine at Mount Sinai · MOUNT SINAI HOSPITAL · Mt. Sinai Hospital Department of Dermatology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Emma Guttman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07242638 · Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down SyndromeIcahn School of Medicine at Mount Sinai · recruiting · Atopic Dermatitis, Alopecia Areata · principal investigator
- Ph2NCT06373458 · Ritlecitinib in Patients With Keloids or Those Undergoing KeloidectomyIcahn School of Medicine at Mount Sinai · recruiting · Keloid · principal investigator
- Ph2NCT05866562 · Dupilumab in the Treatment of Pediatric Alopecia AreataIcahn School of Medicine at Mount Sinai · recruiting · Alopecia Areata · principal investigator
- Ph2NCT05551793 · Regeneron AA Multicenter (Dupilumab)Emma Guttman · recruiting · Alopecia Areata · principal investigator
- Ph2NCT05549934 · Ritlecitinib for Cicatricial AlopeciaEmma Guttman · completed · Cicatricial Alopecia · principal investigator
- Ph2NCT05076006 · Dual JAK1/TYK2 Inhibitor for Cicatricial AlopeciaEmma Guttman · completed · Cicatricial Alopecia · principal investigator
- Ph1NCT05069831 · JAK Inhibition in Food AllergyIcahn School of Medicine at Mount Sinai · completed · Food Allergy · principal investigator
- Ph4NCT04988022 · Dupilumab in the Treatment of KeloidsIcahn School of Medicine at Mount Sinai · completed · Keloid · principal investigator
- Ph2NCT04605094 · Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic DermatitisAstraZeneca · terminated · Atopic Dermatitis · principal investigator
- Ph2NCT03359356 · Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)Icahn School of Medicine at Mount Sinai · completed · Alopecia Areata · principal investigator
- Ph2NCT03041038 · The Efficacy and Safety of Secukinumab in Patients With IchthyosesNorthwestern University · completed · Ichthyosis, Autosomal Recessive Congenital Ichthyosis, Lamellar Ichthyosis · principal investigator
- Ph2NCT02684097 · A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia AreataEmma Guttman · completed · Alopecia Areata · principal investigator
- N/ANCT02684123 · Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia AreataIcahn School of Medicine at Mount Sinai · completed · Alopecia Areata · principal investigator
- Ph2NCT02594098 · Secukinumab for Treatment of Atopic DermatitisIcahn School of Medicine at Mount Sinai · completed · Atopic Dermatitis · principal investigator
- Ph2NCT02561585 · LEO 124249 Ointment in the Treatment of Alopecia AreataLEO Pharma · completed · Alopecia Areata · principal investigator
- N/ANCT02338076 · A Study to Document the Effect of Petrolatum on Innate Immune Responses in the SkinRockefeller University · completed · Skin Disease · principal investigator
- N/ANCT01782703 · Defining the Skin and Blood Biomarkers of Pediatric Atopic DermatitisNorthwestern University · active not recruiting · Atopic Dermatitis, Eczema · principal investigator
- N/ANCT01546298 · Immune Reactions in Contact Dermatitis Affected SkinRockefeller University · completed · Allergic Contact Dermatitis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Developing a Molecular Map of Atopic Dermatitis Across Ethnicity and Severity Subtypes.U01AI152036 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2020 to 2026 · $224,076 awarded in 2026Same name and institution; not confirmed by an ID
- Dupilumab in the Treatment of Pediatric Alopecia AreataU01AI179629 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2024 to 2026 · $1,309,584 awarded in 2026Same name and institution; not confirmed by an ID
- Use of specific JAK inhibition on inflammatory skin and scalp diseases in Down syndromeR33AR084210 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2026 · $1,365,911 awarded in 2026Same name and institution; not confirmed by an ID
- Use of specific JAK inhibition on inflammatory skin and scalp diseases in Down syndromeR61AR084210 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2024 to 2025 · $409,397 awarded in 2025Grant number is on one of their registry trials
- A Study of ILV-94 (Anti-22 Antibody) Administered via IV in Atopic DermatitisUM1AR063917 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2013 to 2017 · $604,490 awarded in 2017Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:24 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed
- Oral orismilast: Efficacy and safety in moderate-to-severe psoriasis and development of modified release tablets.J Eur Acad Dermatol Venereol · 202321 citationsRCR 3.1